Victor J Gallardo
Overview
Explore the profile of Victor J Gallardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gine-Cipres E, Torres-Ferrus M, Gallardo V, Ruiz A, Caronna E, Pozo-Rosich P
Pain Manag Nurs
. 2025 Jan;
PMID: 39799047
Purpose: Headache is a prevalent and highly disabling neurological disorder. There are no data on its prevalence in and impact on hospitalized patients. The objective of this study was to...
2.
Gomez-Dabo L, Caronna E, Mas-de-Les-Valls R, Gallardo V, Alpuente A, Torres-Ferrus M, et al.
Toxins (Basel)
. 2024 May;
16(5).
PMID: 38787073
Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature...
3.
Alpuente A, Gallardo V, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P
J Headache Pain
. 2024 Apr;
25(1):58.
PMID: 38637736
Background: Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology,...
4.
Ikumi N, Marti-Marca A, Torre-Sune A, Cerda-Company X, Vila-Ballo A, Gallardo V, et al.
Cephalalgia
. 2024 Feb;
44(2):3331024241230279.
PMID: 38416486
Background: To date, a number of studies on migraine have cross-sectionally evaluated sensory sensitivity with aversion thresholds/scores along the migraine cycle, reporting a decreased tolerance to sensory stimuli in different...
5.
Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo V, Alpuente A, Torres-Ferrus M, et al.
J Headache Pain
. 2024 Feb;
25(1):21.
PMID: 38347485
Background: Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is...
6.
Torres-Ferrus M, Gallardo V, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P
Cephalalgia
. 2024 Feb;
44(2):3331024231222923.
PMID: 38307497
Background: The present study aimed to describe the prevalence and evolution of depressive symptoms in a cohort of migraine patients treated with anti-CGRP monoclonal antibodies. Methods: This is an exploratory,...
7.
Melgarejo L, Caronna E, Rosell-Mirmi J, Elosua-Bayes I, Alpuente A, Torres-Ferrus M, et al.
Eur J Neurol
. 2023 Oct;
30(12):3877-3885.
PMID: 37791410
Background And Purpose: In clinical practice patients may report migraine worsening as a consequence of COVID-19 (either infection or vaccines), however, data in this area are lacking. We aimed to...
8.
Marti-Marca A, Vila-Ballo A, Cerda-Company X, Ikumi N, Torres-Ferrus M, Caronna E, et al.
J Headache Pain
. 2023 Aug;
24(1):104.
PMID: 37545005
Background: Migraine is a cyclic, neurosensory disorder characterized by recurrent headaches and altered sensory processing. The latter is manifested in hypersensitivity to visual stimuli, measured with questionnaires and sensory thresholds,...
9.
Winsvold B, Harder A, Ran C, Chalmer M, Dalmasso M, Ferkingstad E, et al.
Ann Neurol
. 2023 Jul;
94(4):713-726.
PMID: 37486023
Objective: The objective of this study was to aggregate data for the first genomewide association study meta-analysis of cluster headache, to identify genetic risk variants, and gain biological insights. Methods:...
10.
Torres-Ferrus M, Gallardo V, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P
Eur J Neurol
. 2023 Apr;
30(7):1937-1944.
PMID: 37038303
Background And Purpose: The response pattern to monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAbs) shown in migraine prevention clinical trials is not always reproducible at an individual level. This...